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Dendritic cells (DCs) of the skin have an important role in skin-mediated immunity capable of promoting potent
immune responses. We availed of polymeric dissolving microneedle (MN) arrays laden with nano-encapsulated
antigen to specifically target skin DC networks. This modality of immunization represents an economic, efficient,
and potent means of antigen delivery directly to skin DCs, which are inefficiently targeted by more conventional
immunization routes. Following MN immunization, Langerhans cells (LCs) constituted the major skin DC subset
capable of cross-priming antigen-specific CD8þ T cells ex vivo. Although all DC subsets were equally efficient in
priming CD4þ T cells, LCs were largely responsible for orchestrating the differentiation of CD4þ IFN-g- and IL-17-
producing effectors. Importantly, depletion of LCs prior to immunization had a profound effect on CD8þ CTL
responses in vivo, and vaccinated animals displayed reduced protective anti-tumor and viral immunity.
Interestingly, this cross-priming bias was lost following MN immunization with soluble antigen, suggesting that
processing and cross-presentation of nano-particulate antigen is favored by LCs. Therefore, these studies
highlight the importance of LCs in skin immunization strategies and that targeting of nano-particulate
immunogens through dissolvable polymeric MNs potentially provides a promising technological platform for
improved vaccination strategies.
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INTRODUCTION
Elucidation of the mechanisms that underpin the functional
specialization of distinct dendritic cell (DC) populations is
important for the development of improved immunotherapies
and the generation of DC-targeted vaccines, particularly in the
skin, which represents an attractive site for vaccine delivery
(Romani et al., 2010). In normal epidermis, langerin
(CD207)-expressing Langerhans cells (LCs) constitute the
only population of professional antigen-presenting cells,
whereas the dermis harbors three distinct CD207þ DC
subsets: migratory LCs, CD207þ CD103þ and CD207þ
CD103 dermal DCs (dDCs), in addition to two CD207
dDC subsets, characterized by differential expression of
CD11b (Henri et al., 2010).
Numerous studies have highlighted significant in vivo func-
tional heterogeneity among skin DC populations. CD207þ
dDCs appear to be required for protective immunity in a
number of infection and vaccination models, whereas the
precise contribution of LCs in promoting immune responses
in vivo remains controversial. Several studies have questioned
whether LCs are required for the generation of protective
antigen-specific immune responses in different mouse models
(Zhao et al., 2003; Ritter et al., 2004; Kautz-Neu et al., 2011),
whereas studies permitting the conditional or constitutive
ablation of CD207þ DCs suggest that LCs instigate antigen-
specific unresponsiveness or tolerance under homeostatic
conditions (Henri et al., 2010; Schwarz et al., 2010; Idoyaga
et al., 2013). Another unresolved question is whether LCs are
capable of efficient cross-priming antigen in vivo (Romani
et al., 2012), with numerous models attributing this role
primarily to CD207þ dDCs and lymph node (LN) resident
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CD8þ DCs (Igyarto and Kaplan, 2013). LCs have been shown
to stimulate type 2T-helper (Th) cell responses (Hauser et al.,
1989; Stoecklinger et al., 2011); however, LCs have been
shown to also evoke Th1 cell responses or activate Th17
cells (Duraisingham et al., 2009; Mathers et al., 2009; Igyarto
et al., 2011).
In this study, we entrapped the model antigen, ovalbumin
(OVA), into poly-D-L- lactide-co-glycolide (PLGA) nanoparti-
cles (NPs), as these particles were previously shown
to have strong immune-modulatory properties and activate
DCs to induce efficient T-cell immune responses (Gutierro
et al., 2002; Jaganathan and Vyas, 2006). Previous studies
have demonstrated the capacity of model protein antigens,
inactivated or subunit vaccines to prime adaptive immunity
when delivered via MN arrays (Sullivan et al., 2010;
Kim et al., 2012). To this end, we employed biodegradable
polymeric dissolvable MNs to specifically target NP-encap-
sulated antigen to DCs within the different skin compartments
to enhance their activation and promote adaptive
immunity. Recently, we demonstrated that MN-mediated
delivery of nano-encapsulated antigen efficiently targeted
skin DCs, which in turn induced efficient T-cell responses
(Zaric et al., 2013). However, the contribution of individual
skin DC subsets in the induction of immune responses
using our vaccination strategy was not examined in detail.
Utilizing skin DC ablation models, we demonstrate
that following MN-mediated NP-immunization, LCs are
central in cross-priming antigen in vivo and inducing
Th1 and Th17 immune responses by antigen-specific
CD4þ T cells. Importantly, we highlight the prerequisite
for LCs to generate both antigen-specific anti-tumor
and anti-viral immune responses following antigen-NPs MN
immunization.
RESULTS
LCs are the major population capable of cross-priming
CD8þ T cells
To determine the contribution of specific DC subsets following
intradermal immunization, dissolvable MNs containing
OVA-encapsulated NPs (OVA-NPs) were applied to LangeGFP
mouse ears, and DC subsets from pooled auricular LNs were
purified by FACS 24 and 72 hours post immunization. Skin-
derived DCs (CD11cþ MHCIIhighCD8 ) were sorted
into distinct DC subsets on the basis of eGFP, CD103,
and Ep-CAM expression (Supplementary Figure S1 online).
Following coculture of purified skin DCs with carboxyfluor-
escein diacetate succinimidyl ester (CFSE)-labeled
OVA-specific OT-I CD8þ or OT-II CD4þ T cells, we found
that LCs constituted the major subset able to cross-present
OVA-NPs, although a low degree of antigen presentation to
CD8þ OT-I T cells was mediated by other dDC subsets
(Figure 1a and b). In contrast, all skin DC subsets were equally
able to efficiently activate and induce CD4þ OT-II cell pro-
liferation in vitro (Figure 1c and d). Because of their observed
slower migration to the draining LNs (Kissenpfennig et al.,
2005), LC-induced OT-I and OT-II T cell proliferation peaked
at 72 hours post MN vaccination. Importantly, delivery of
tetramethylrhodamine NPs via MN application demonstrated
that NPs were equally taken up by all skin DC subsets in vivo
(Supplementary Figure S2 online). Therefore, LCs are the
predominant skin DC subset that contribute to cross-priming
of naive antigen-specific CD8þ T cells following immuniza-
tion with dissolvable MNs laden with antigen-encapsulated
NPs. However, no observed bias by the specific skin DC
subsets could be discerned for antigen presentation and/or
activation of CD4þ T cells.
LCs are necessary for optimal cross-presentation in vivo
To substantiate our findings with ex vivo skin DCs in an in vivo
system, we employed our LanghDTR model and depleted
CD207þ DCs prior to immunization (Kissenpfennig et al.,
2005). To deplete LCs only, LanghDTR mice were treated
intraperitoneally with a single dose of diphtheria toxin (DT) 7
days prior to MN immunization, or a supplementary DT dose
was given 1 day prior to immunization to deplete both LCs and
CD207þ dDC, consistent with previously published studies
(Supplementary Figure S3 online; Bursch et al., 2007; Ginhoux
et al., 2007; Poulin et al., 2007). One day prior to blank NP (b-
NP) or OVA-NP immunization, DT-untreated or -treated
LanghDTR mice were adoptively transferred with CFSE-labeled
CD8þ T cells purified from CD45.1 congenic OT-I mice.
Expansion of donor CD8þ cells in auricular LNs was analyzed
7 days post MN immunization. As expected, efficient expansion
of antigen-specific CD45.1þ CD8þ T cells was detected
following immunization with OVA-NPs compared with mice
immunized with b-NPs. In contrast, expansion of OVA-specific
CD8þ T cells was significantly reduced in LanghDTR mice
receiving either DT dosing regimes (Figure 2a). Interestingly, all
skin DC subsets had the capacity to induce efficient IFN-g
production among proliferating OT-I cells, notwithstanding that
absolute numbers of IFN-gþ OT-I T cells were significantly
reduced in the absence of LCs (Figure 2b).
These observations were substantiated in a genuine in vivo
model by examining the expansion of endogenous OVA-
specific CD8þ T cells following MN immunization with
b-NPs or OVA-NPs. Utilizing the same immunization and
depletion protocol described above, isolated auricular LN
cells were stained with OVA257–264/H-2K
b pentamers specific
for the SIINFEKL epitope of OVA protein 2 weeks post
immunization. MN immunization with OVA-NPs resulted in
increased percentages and total numbers of OVA-specific
CD8þ T cells in DT-untreated mice compared with mice that
had received one or two doses of DT prior to immunization
(Figure 2c), reaffirming the requirement for LCs for optimal
cross-presentation of nano-encapsulated antigen following
MN intradermal immunization.
LCs promote Th1 and Th17 CD4þ T-cell differentiation
To examine Th immune responses by different skin-derived
DC subsets, we adoptively transferred CD45.1þ CD4þ OT-II
T cells into LanghDTR mice prior to DT treatment and MN
immunization. No difference in total numbers of donor OT-II
cells was observed between mice with LCs, and mice lacking
LCs only, or both LCs and CD207þ dDCs (Figure 3a and b),
confirming that both CD207þ and CD207 dDCs were
equally capable of presenting OVA-NPs and activating
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CD4þ Th cells. The cytokine profile of expanded CD45.1þ
OT-II T cells revealed that the polarization of IFN-g- and
IL-17A-producing cells necessitated the presence of LCs
(Figure 3c and d), whereas only a few OT-II cells polarized
toward IL-4-producing Th2 cells. Interestingly, in the absence
of LCs, the number of donor OT-II cells producing IL-4 was
significantly elevated. Of note, we did not observe any notable
difference in the induction of Foxp3-producing OT-II T cells in
our model. Therefore, the absence of LCs has a profound
effect on the development of Th1 and Th17 cells following
MN-mediated delivery of nano-particulate antigen.
LCs are necessary for efficient anti-tumor responses following
microneedle (MN) immunization
We further examined the contribution of LCs in antigen-
specific anti-tumor immune responses. Utilizing the same
depletion and immunization strategy as in previous experi-
ments, LanghDTR mice were challenged 3 weeks post
MN-vaccination with B16.OVA tumor cells, and tumor
growth was monitored thereafter. As expected, DT-untreated
LanghDTR mice immunized with OVA-NPs were protected
against tumor challenge, whereas all mice immunized with
b-NPs exhibited expected tumor growth. In OVA-NPs immu-
nized mice depleted of LCs only, or both LCs and CD207þ
dDCs, tumors grew at a reduced rate and mice survived longer
compared with b-NPs immunized mice (Figure 4a and b),
suggesting that all skin DCs contribute to anti-tumor immunity
following MN-mediated intradermal immunization. However,
mice with LCs present developed smaller tumors and survived
significantly longer compared with DT-treated animals
(Figure 4a and b), highlighting the importance of LCs for
optimal anti-tumor immunity in this model. Furthermore,
staining of tumor cell suspensions with OVA257–264/H-2K
b
pentamers identified a clear population of OVA-specific
tumor-infiltrating CD8þ T cells in DT-untreated mice, which
was found to be 3- to 5-fold reduced in mice lacking LCs or all
CD207þ skin DCs at the time of OVA-NPs immunization
(Figure 4c). Similarly, the percentages of tumor-infiltrating
total CD8þ T cells were increased in DT-untreated mice
compared with mice that had received one or two doses of DT
prior to immunization (Supplementary Figure S4 online).
To determine the contribution of skin DC subsets in evoking
therapeutic anti-tumor immunity, DT-treated and -untreated
LanghDTR mice were first injected into the flank with B16.OVA
tumor cells, and on days 4 and 9 following tumor inoculation
they were immunized with MNs (Supplementary Figure S5
online). Only tumors from OVA-NPs immunized DT-untreated
animals were significantly affected. These tumors were nota-
bly smaller compared with tumors from b-NPs immunized
mice 15 days post tumor inoculation, suggesting that the
presence of all skin DC subsets in the skin at the time of
immunization is necessary for robust anti-tumor activity in a
therapeutic setting (Figure 4d). Mice survival determined by
tumor volume end point between different experimental
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Figure 1. All skin-derived dendritic cell (DC) subsets present antigen to CD4þ T cells, but Langerhans cells (LCs) are the major population capable of cross-
priming CD8þ T cells ex vivo. Mice (n¼ 20) were immunized through microneedles (MNs) with ovalbumin (OVA)-encapsulated nanoparticles, and following
24 hours or 72 hours defined subsets of DCs from auricular lymph nodes were purified by FACS. 5 104 OVA-specific CD8þ or CD4þ T cells were cocultured in
triplicates with 5 103 DCs of each subset for 60 hours. (a) Representative histograms of carboxyfluorescein diacetate succinimidyl ester (CFSE) dilutions of OT-I
cell proliferation. (b) Bar graphs representing the percentage of proliferating OT-I T cells. (c) Representative histograms of CFSE dilutions of OT-II cell proliferation.
(d) Bar graphs representing the percentage of proliferating OT-II T cells. Data have been pooled from two separate experiments.
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groups found that irrespective of the presence of LCs, treat-
ments with OVA-NPs MNs prolonged overall survival of mice
compared with mice treated with b-NPs MNs. However,
survival was further improved if LCs were present in the skin
at the time of OVA-NPs MN immunization (Figure 4e).
LCs are required for effective anti-viral responses following MN
immunization
To test the capacity of different skin-derived DC subsets to
promote protective viral immunity following MN-mediated
vaccination in a murine para-influenza virus model, we
utilized a recombinant Sendai virus expressing an OVA/red
fluorescent fusion protein (SeVOVATdT; Zaric et al., 2013).
LanghDTR mice were either untreated or treated with DT,
immunized with b-NPs or OVA-NPs, and 3 weeks later
intranasally challenged with SeVOVATdT. All b-NPs immunized
animals did not survive beyond 6 days post challenge
(Figure 5a). When depleted of LCs, OVA-NPs immunized
mice presented with significantly reduced survival compared
with DT-untreated controls that all survived the challenge.
Analysis of whole lung cell suspensions revealed significantly
increased percentages of SeVOVATdT-positive cells in b-NPs
immunized mice compared with untreated OVA-NPs immu-
nized animals. Furthermore, there was a 3- to 5-fold increase
in the percentages of SeVOVATdT-positive cells in mice lacking
LCs or both LCs and CD207þ dDCs compared with mice with
their full complement of skin DCs (Figure 5b and c). Lung viral
titer measurements confirmed significantly higher viral titers
in DT-treated OVA-NPs immunized mice compared with
DT-untreated mice, where viral titers were below detection
levels (Figure 5d).
Analysis of lung cell suspensions 6 days post challenge
revealed that OVA-specific CD8þ T cells could consistently
be detected in the lungs of OVA-NPs immunized mice
(Figure 5e), whereas this population was 2- to 3-fold reduced
when LCs or all CD207þ -expressing skin DCs were depleted
at the time of MN immunization. We did not observe any
significant differences in the ability of LCs or CD207þ and
CD207 dDC subsets to activate IFN-g- and/or Granzyme
B–expressing CD8þ T cells, as the proportion of IFN-gþ and
Granzyme Bþ OVA-specific T cells remained similar between
the different DT treatment groups (Figure 5f). Collectively,
these results demonstrate that the presence of LCs in the skin
at the time of immunization with MNs laden with antigen-NPs
is essential for promoting the activation and expansion of
antigen-specific CD8þ T cells contributing to the complete
protection against pulmonary viral challenge.
Effective LC cross-presentation is dependent on nano-
encapsulation of antigen
Although our results suggest that LCs represented the predomi-
nant DC subset capable of cross-priming nano-encapsulated
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Figure 2. LCs are the major skin dendritic cell (DC) subset capable of antigen cross-presentation in vivo. LanghDTR mice that were either untreated (diphtheria
toxin (DT )) or treated with DT once (DTþ ) or twice (DTþ þ ), received in vivo 106 carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled, CD45.1 OT-
I cells. Mice were immunized with blank nanoparticles (b-NPs) or ovalbumin-encapsulated nanoparticles (OVA-NPs) the following day and skin-draining LNs
were harvested 7 days later. (a) Percentages and total numbers of CD45.1þ OT-I cells recovered within each experimental group are shown. (b) CFSE and
expression of IFN-g among CD8þCD45.1þ cells (left panel) and total numbers of IFN-g-producing OT-I cells within each group are shown (right panel). (c)
Percentages and total numbers of endogenous OVA257–264/H2K
bþCD8þ T cells detected in the auricular LNs among different experimental groups are shown. All
flow cytometric dot plots represent an individual mouse from each experimental group obtained in one out of three separate experiments.
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antigen following MN delivery, it was unclear whether
preferential activation of antigen-specific CD8þ T cells by
LCs occurred as a consequence of antigen nano-encapsulation
or MN-mediated antigen delivery. Therefore, we directly
compared the ability of different skin-derived DC subsets to
cross-present antigen delivered by MNs, as either a nano-
particulate or a non-nano-particulate formulation. MNs con-
taining either OVA-NPs or the comparable amount of OVA
were applied to mouse ears, and DC subsets from auricular
LNs were purified by FACS 72 hours post immunization as
previously described. Following coculture of DC subsets with
CFSE-labeled OT-I cells, we confirmed that nano-particulate
antigen was again predominantly cross-presented by LCs.
In contrast, MN delivery of soluble OVA demonstrated
that CD207þ CD103þ dDCs were the major population
responsible for antigen cross-presentation (Figure 6a). All other
skin-derived DC subsets, including LCs, can to some extent,
cross-present soluble antigen; however, the degree of T-cell
activation by these subsets was significantly reduced in
comparison with CD207þ CD103þ dDCs (Figure 6b). Impor-
tantly, these experiments suggest that the physical nature of
the immunogen could impact the functional specialization of
skin DCs following intradermal immunization. CD207þ
CD103þ dDCs were found to have a superior ability to
cross-prime soluble antigen, whereas cross-presentation of
nano-encapsulated antigen was strongly favored by LCs.
DISCUSSION
Ongoing research in skin DC immunobiology, together with
the development of new technologies for manipulating DCs,
highlights their promising potential in the prevention and
treatment of various infectious diseases and cancer (Romani
et al., 2010). However, skin DC populations are hetero-
geneous, composed of phenotypically and functionally
diverse subsets, and ensuing immune responses may be
influenced by the subset of DC involved. Several studies
designed to test LC-mediated cross-presentation in vitro or
ex vivo have confirmed their ability to efficiently present
exogenously acquired antigen to antigen-specific CD8þ
T cells (Stoitzner et al., 2006; Klechevsky et al., 2008). In
line with Stoitzner et al. (2006), we show here that LCs are
also able to efficiently cross-present nano-encapsulated
antigen to OT-I T cells ex vivo following MN-mediated
OVA-NPs immunization.
Extensive data to demonstrate LC cross-presentation
in vivo have been limited (Igyarto and Kaplan, 2013).
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Figure 3. Langerhans cells promote T-helper (Th)1 and Th17 CD4þ T-cell differentiation. Diphtheria toxin (DT)-untreated or -treated LanghDTR mice received
intravenous 106 CD45.1 OT-II cells. Mice were immunized with blank nanoparticles (b-NPs) or ovalbumin-encapsulated nanoparticles (OVA-NPs) the following
day and skin-draining lymph nodes (LNs) were harvested 7 days later. (a) Percentages and total numbers of CD45.1þ CD4þT cells recovered within each
experimental group are shown. (c) Total LN cells were restimulated with phorbol 12 myristate 13 acetate-Ionomycin prior to intracellular staining. The expression
of IFN-g and IL-4 among CD4þ CD45.1þ gated cells is shown. (c) The same as in b, but the expression of IL-17 and Foxp3 among different experimental groups is
shown. (d) Total numbers (mean±SEM, n¼ 6/group) of IL-4, IFN-g, IL-17, or Foxp3 expressing OT-II cells within each group.
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To date, cross-presentation of cutaneous antigen has been
shown to be dependent on CD207þ CD103þ dDCs (Bobr
et al., 2010; Stoecklinger et al., 2011), whereas we observed
only modest antigen cross-priming by dDCs following
NPs-MN immunization. In addition, we cannot completely
exclude that monocyte-derived infiltrating inflammatory DCs
(Cheong et al., 2010) played an additional role in cross-
priming. However, they have been shown to be poorly
represented in the skin DC migratory fraction of LNs and
had reduced capacity for naive T-cell activation in vivo
(Tamoutounour et al., 2013). In contrast to nano-
encapsulated antigen, our data suggest that delivery of
soluble antigen was most efficiently presented by CD207þ
CD103þ dDCs rather than LCs. Indeed, the ability of
CD207þ CD103þ dDCs to cross present skin-borne antigens
to CD8þ T cells has been confirmed in several models, such
as keratinocyte-restricted expression of OVA and infec-
tion models of Leishmaniasis, Candida albicans, HSV, and
Vaccinia virus (Bedoui et al., 2009; Brewig et al., 2009; Henri
et al., 2010; Igyarto et al., 2011; Seneschal et al., 2014).
The specific downstream intracellular mechanisms follow-
ing PGLA-NP uptake, antigen processing and presentation by
DCs, and their activation in our vaccination model remain
poorly understood. PLGA NPs have been shown to specifi-
cally activate the NLRP3 inflammasome (Sharp et al., 2009;
Yang et al., 2013). MN-mediated PLGA-NP vaccination likely
activates DC inflammasome signaling pathways, and this
could bias the cross-priming capability of LCs. Furthermore,
a possible role of Birbeck’s granules, a unique organelle of
LCs, in controlling intracellular fate of particulate antigens
cannot be dismissed, and further investigation into PLGA-NP
LC compartmentalization following uptake and induced
activation of LCs is warranted.
A recent study, utilizing Na-CMC/sucrose dissolvable MN
arrays loaded with live recombinant adenovirus vector or
Texas Red-Dextran, demonstrated that CD8þ T-cell immune
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groups (n¼ 9/group) are shown.
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Figure 5. Langerhans cells are required for effective anti-viral immunity (a). LanghDTR mice, either diphtheria toxin (DT) untreated or treated, were immunized
with blank nanoparticles (b-NPs) or ovalbumin-encapsulated nanoparticles (OVA-NPs) microneedles (MNs). Mice were challenged intranasally with SeVOVATdT 3
weeks later. Survival among experimental groups following SeVOVATdT challenge (n¼8–10/group) is shown. (b) Representative dot-plots indicating percentages of
SeVOVATdT-positive cells in total lung cell suspensions between groups 6 days post infection. (c) Bars indicating percentage of SeVOVATdT-positive cells in total lung
cell suspensions between groups (n¼ 10/group). (d) Viral titers in lung homogenates between groups at 6 days post infection. (e) Percentages of OVA-specific
CD8þT cells infiltrating the lungs between immunization groups. (f) IFN-g and/or Granzyme B production following phorbol 12 myristate 13 acetate/Ionomycin
restimulation of OVA-specific CD8þT cells infiltrating the lungs, as analyzed 6 days post SeVOVATdT challenge.
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Figure 6. CD207þCD103þ dermal DCs (dDCs) preferentially cross-present soluble antigen delivered following microneedle (MN) immunization. Mice (n¼ 20/
group) were immunized through MNs with ovalbumin-encapsulated nanoparticles (OVA-NPs) or soluble OVA, and following 72 hours defined subsets of dendritic
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two separate experiments and are represented as mean±SEM. LC, Langerhans cell.
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responses to adeno-viral vectors or uptake of Texas Red-
Dextran was largely attributed to the CD11bþ CD207 dDC
subset (Bachy et al., 2013). Uptake of particulate antigens by
DCs is dependent on several antigen-associated properties,
such as size, shape, surface charge, hydrophobicity/hydro-
philicity, as well as receptor interactions. Indeed, without
specific recognition, PLGA-NPs are naturally targeted to DCs
through phagocytosis, whereas adenovirus viral uptake has
been shown to be receptor mediated through clathrin-
mediated endocytosis and protein kinase C–dependent
macro-pinocytosis (Meier and Greber, 2003; Hamdy et al.,
2011). Likewise, subsequent activation of innate signaling
pathways following viral or PLGA NPs internalization may
differ. Interestingly, a recent study demonstrated that following
plasmid DNA intradermal vaccination, CD8þ T cell cross-
priming was largely instigated by infiltrating, second genera-
tion antigen-expressing LCs (Elnekave et al., 2014). Therefore,
the perceived defined functional allocations among distinct skin
DC subsets may not necessarily exist, but rather the underlying
mechanisms that govern antigen processing, presentation, and
activation of DCs may influence their subsequent functional
properties and the net immune response.
MN delivery of antigen-NPs to skin DCs led to efficient
priming of antigen-specific CD4þ T cells, irrespective of the
presence of LCs. However, LCs were primarily required for
Th1 and Th17 development. Similarly, it has been shown that
direct presentation of C. albicans-derived antigen by LCs was
necessary for the generation of antigen-specific Th17 effectors
(Igyarto et al., 2011). Contrary, Fujita et al. (2009) showed that
LCs induced IL-22-producing CD4þ T cells, which at the
same time lacked the expression of IL-17 and IFN-g.
Therefore, the importance of LCs in maintaining mucosal
homeostasis and for Th17 effector responses in our
immunization modality would require further confirmation
in an appropriate pathogenic model.
Finally, we demonstrate that LCs are necessary for the
induction of protective antigen-specific anti-viral and anti-
tumor immunity. The absence of LCs had a marked effect on
the ability of Sendai-infected animals to efficiently clear
pulmonary viral infection. This is supported by the observation
that selective depletion of LCs in vivo at the time of MN
vaccination was sufficient to significantly diminish the expan-
sion of antigen-specific infiltrating CD8þ T cells, confirming
that dDCs had a secondary contributory role in cross-priming
nano-encapsulated antigen. However, dDCs subsets still
mediated some delay in tumor growth and prolonged mice
survival. In mice immunized with OVA-NPs and depleted of
LCs, or both LCs and CD207þ dDCs, tumors grew at a
significantly decreased rate and mice survived longer com-
pared with b-NPs immunized mice, suggesting that dDCs
were in part necessary for effective anti-tumor immunity.
Indeed, it has recently been shown that CD207 CD11b
dDCs may be an important contributor to the cutaneous
immune environment (Mollah et al., 2014). Moreover,
depletion of both LCs and CD207þ dDCs showed an
appreciable trend in increased tumor volumes and inferior
survival in comparison with mice lacking only LCs, indicating
that CD207þ dDCs may beneficially contribute to anti-tumor
immunity. Therefore, whether LCs alone are sufficient to
induce this anti-tumor and anti-viral response or synergy
with other DC subsets is required remains to be determined.
Importantly, the fact that tumor and viral challenges were
performed 3 weeks post immunization indicates that LCs were
also involved in the induction of memory response. Indeed,
we have previously confirmed that OVA-NPs MN immuniza-
tion induced antigen-specific memory response in mice
challenged with tumor cells 3 weeks post vaccination (Zaric
et al., 2013). However, more long-term challenge studies are
required to confirm this observation.
Despite changing paradigms, LCs remain an essential cell in
the immune system of the skin, at least in the context of
antigen-NPs delivery through MNs. Emerging nano-technolo-
gical advances in drug delivery coupled with self-disabling,
biodegradable, dissolving MN arrays offer an exciting prospect
for delivery of antigens to easily accessible skin DC popula-
tions to improve vaccine efficacy. Therefore, these results
provide a strong rationale for more in-depth exploration of
therapies based on MN-mediated antigen-NP targeting of LCs
for the treatment of infectious diseases and tumors.
MATERIALS AND METHODS
Full details of methods are described in Supplementary Materials and
Methods online.
Fabrication of NP-loaded MNs
MNs prepared from aqueous blends of 20% w/w PMVE/MA were
fabricated using laser-engineered silicone micro-mould templates
(Donnelly et al., 2011). MN arrays (19 19 array, 600mm height)
containing PLGA NPs were prepared as previously described (Zaric
et al., 2013).
Mice
Transgenic mice, including LangeGFP reporter mice, LanghDTR mice
(Kissenpfennig et al., 2005), and OT-I and OT-II mice (The Jackson Lab,
Bar Harbor, ME; Hogquist et al., 1994; Barnden et al., 1998) on a
congenic CD45.1 C57BL/6 background were housed under specific
pathogen-free conditions. All mice employed for experiments were
between 6 and 10 weeks of age, age and sex matched, and were
sanctioned in accordance with the UK Home Office and approved by
Queen’s University Belfast Animal Welfare and Ethical Review Board.
MN immunization
MNs containing 10mg OVA-encapsulated NPs or b-NPs, or soluble
OVA were applied to the dorsal side of both ears. The MNs were held
in place for at least 5 minutes and then removed.
Depletion of LCs or CD207þ dDCs
For systemic in vivo depletion of CD207þ DCs, LanghDTR mice were
injected intraperitoneally with 1mg DT (Quadratec Diagnostics,
Surrey, UK) using the specified timing of application.
Reagents for flow cytometry
Surface marker expression was assessed by flow cytometry using
fluorochrome-conjugated antibodies (BD Biosciences, Oxford, UK and
eBioscience, Hatfield, UK), and PE-labeled Kb/SIINFEKL pentamers
were purchased from ProImmune, Oxford, UK.
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In vivo proliferation assays
Mice were injected intravenously with 106 CFSE-labeled OT-I or OT-
II T cells, 24 hours prior to MN immunization. Mice were sacrificed
7 days following MN application, and auricular LNs were harvested
for FACS analysis.
Ex vivo proliferation assay
DCs sorted from the auricular LNs 24 hours or 72 hours post MN
immunization were cocultured in triplicates with CFSE-labeled
OVA-specific OT-I or OT-II T cells for 60 hours in a 1:10 ratio, and
proliferation of T cells was measured by the decrease in CFSE
fluorescence intensity.
Tumor challenge
Three weeks following MN immunization, mice were injected
subcutaneously into the flank with 105 B16.OVA tumor cells
(Brown et al., 2001; kindly provided by Stoitzner et al. (2006),
Innsbruck). Tumor size was assessed by measuring the short and long
tumor diameters using digital callipers. Measurements were stopped
when tumor diameter reached maximum allowed dimension of
20 mm and mice had to be euthanized, according to UK Home
Office guidelines and Queens University Belfast ethical review
committee guidelines.
Challenge of mice with recombinant Sendai virus-OVA-TdT
(SeVOVA TdT)
Experimental groups of mice were challenged 3 weeks after
MN immunization by intranasal instillation of 2 106 p.f.u.
SeVOVA TdT (Zaric et al., 2013) in 30 ml of PBS and monitored for
up to 7 days.
Statistical analysis
Bars in figures show the mean±SEM. All numerical data were
analyzed for significal differences between groups by analyses of
variance with Prism software 5.0 (PRISM GraphPad Software, La Jolla,
CA). Probability values are expressed as the following: ***Po0.001;
**Po0.01; and *Po0.05.
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